{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T20:39:06Z","timestamp":1759178346425,"version":"3.41.2"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T00:00:00Z","timestamp":1679270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003286","name":"Kuwait Foundation for the Advancement of Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003286","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>People with diabetes are at a higher risk for coronavirus disease-19 (COVID-19) and hence are prioritized for vaccination. The aim of the current study was to investigate the effects of COVID-19 vaccination on blood glucose control in Arabic people with type 1 diabetes (T1D). Secondary aim was to compare the responses between the two vaccines approved for use in Kuwait.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>This retrospective study compared ambulatory glucose metrics, using a continuous glucose monitoring device, measured for 14 days before, and 7 days and 14 days after, the first and second dose of the COVID-19 vaccine in Arabic people with Type 1 diabetes (T1D). We also explored possible links with vaccine type and other clinical characteristics. Glucose metrics calculated were time in range (TIR, 3.9\u201310 mmol\/L), time above range (TAR, 10.1- 13.9 mmol\/L or &amp;gt;13.9 mmol\/L), time below range (TBR, 3- 3.9 mmol\/L or &amp;lt;3 mmol\/L) and glucose variability (CV).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We enrolled 223 participants in the study. Over the 7 days period after the first vaccination dose there was a decrease in TIR (mean difference (SD) \u20131.9% \u00b1 14.8%; p = 0.05) and increase in TAR &amp;gt;10 mmol\/L (2.2% \u00b1 15.9%; p = 0.04), with no effects on TBR. These effects were not seen after the second dose or 14 days after either dose. There was a decrease in CV over the 7 days period after the first (\u22121.2% \u00b1 7.4%; p = 0.02) and second vaccine doses (\u22121.1% \u00b1 6.9%; p = 0.03), with no effects noted 14 days after either dose. In subgroup analysis similar effects on TIR and TAR were also seen in those who had received the viral vector-based vaccine, but not the mRNA-based vaccine, although the decrease in CV was seen in those who had received the mRNA based vaccine but not the viral vector-based vaccine.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>We found a temporary impairment in glucose control in the first 7 days, particularly among individuals receiving viral vector vaccines. The group receiving mRNA vaccine was likely to experience an increase in glucose levels above the target range. However, the temporary change in metrics appears to return to pre-vaccination levels after one-week post-vaccination. The effects on glycemic parameters were more neutral after the second dose.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2023.1120384","type":"journal-article","created":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T05:50:27Z","timestamp":1679291427000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Effect of COVID-19 vaccine on blood glucose metrics in Arabic people with type 1 diabetes"],"prefix":"10.3389","volume":"14","author":[{"given":"Ebaa","family":"Al-Ozairi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Irshad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Etab","family":"Taghadom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anisha","family":"Varghese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Litty","family":"Sojan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jumana","family":"Alkandari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.2337\/dci21-0002","article-title":"COVID-19 and type 1 diabetes: Addressing concerns and maintaining control","volume":"44","author":"DiMeglio","year":"2021","journal-title":"Diabetes Care"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(21)00017-6","article-title":"COVID-19 vaccine prioritisation for type 1 and type 2 diabetes","volume":"9","author":"Powers","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe2034906","article-title":"Audio interview: SARS-CoV-2 vaccination and vulnerable populations","volume":"383","author":"Rubin","year":"2020","journal-title":"Mass Med Soc"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.7326\/M21-0367","article-title":"The dual burden of type 1 diabetes and COVID-19","volume":"174","author":"Gregory","year":"2021","journal-title":"Ann Internal Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcmed.2020.07.005","article-title":"Diabetes mellitus is associated with severe infection and mortality in patients with COVID-19: A systematic review and meta-analysis","volume":"51","author":"Shang","year":"2020","journal-title":"Arch Med Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.589833","article-title":"Adjuvants for coronavirus vaccines","volume":"11","author":"Liang","year":"2020","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s12916-021-02059-5","article-title":"Evaluation of the safety profile of COVID-19 vaccines: A rapid review","volume":"19","author":"Wu","year":"2021","journal-title":"BMC Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbaa340","article-title":"Design of an epitope-based peptide vaccine against the SARS-CoV-2: A vaccine-informatics approach","volume":"22","author":"Alam","year":"2021","journal-title":"Briefings Bioinf"},{"key":"B9","doi-asserted-by":"publisher","first-page":"102271","DOI":"10.1016\/j.dsx.2021.102271","article-title":"COVID-19 vaccine hesitancy among patients with diabetes in Saudi Arabia","volume":"15","author":"Aldossari","year":"2021","journal-title":"Diabetes Metab Syndrome: Clin Res Rev"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2027160","DOI":"10.1080\/21645515.2022.2027160","article-title":"The efficacy and effectiveness of the COVID-19 vaccines in reducing infection, severity, hospitalization, and mortality: A systematic review","volume":"18","author":"Mohammed","year":"2022","journal-title":"Hum Vaccines Immunother"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.14714","article-title":"Analysis of continuous glucose tracking data in people with type 1 diabetes after COVID-19 vaccination reveals unexpected link between immune and metabolic response, augmented by adjunctive oral medication","volume":"75","author":"Heald","year":"2021","journal-title":"Int J Clin Pract"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2020.04.24.050534","DOI":"10.1101\/2020.04.24.050534","article-title":"ACE2 homo-dimerization, human genomic variants and interaction of host proteins explain high population specific differences in outcomes of COVID19","volume":"2020","author":"Sharma","year":"2020","journal-title":"bioRxiv"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.3390\/jcm9072288","article-title":"Clinical management of diabetes mellitus in the era of COVID-19: Practical issues, peculiarities and concerns","volume":"9","author":"Koliaki","year":"2020","journal-title":"J Clin Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.940357","article-title":"Immunogenicity of COVID-19 vaccines in patients with diabetes mellitus: A systematic review","volume":"13","author":"Boroumand","year":"2022","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2337\/db22-0053","article-title":"Immunogenicity and safety of SARS-CoV-2 mRNA vaccines in a cohort of patients with type 1 diabetes","volume":"71","author":"D'Addio","year":"2022","journal-title":"Diabetes"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-021-01837-0","article-title":"Interstitial glucose monitoring, type 1 diabetes and COVID-19 vaccine: The patient-reported outcomes and vaccine-associated changes in glucose and side effects (PRO-VACS)","volume":"59","author":"Dicembrini","year":"2022","journal-title":"Acta Diabetol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"102371","DOI":"10.1016\/j.dsx.2021.102371","article-title":"Diabetic ketoacidosis (DKA) in type 1 diabetes mellitus (T1DM) temporally related to COVID-19 vaccination","volume":"16","author":"Ganakumar","year":"2022","journal-title":"Diabetes Metab Syndr"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.840580","article-title":"A case series of ketoacidosis after coronavirus disease 2019 vaccination in patients with type 1 diabetes","volume":"13","author":"Yakou","year":"2022","journal-title":"Front Endocrinol"},{"volume-title":"Statistical power analysis for the behavioral sciences","year":"1988","author":"Cohen","key":"B19"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.1089147","article-title":"Effectiveness of virtual mindfulness-based interventions on perceived anxiety and depression of physicians during the COVID-19 pandemic: A pre-post experimental study","volume":"13","author":"Al Ozairi","year":"2023","journal-title":"Front Psychiatry"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-1563","article-title":"Impact of COVID-19 vaccination on glycemia in individuals with type 1 and type 2 diabetes: Substudy of the COVAC-DM study","volume":"45","author":"Aberer","year":"2021","journal-title":"Diabetes Care"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/dme.14774","article-title":"The change in glycaemic control immediately after COVID-19 vaccination in people with type 1 diabetes","volume":"39","author":"Heald","year":"2022","journal-title":"Diabet Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-022-01885-0","article-title":"A nationwide survey of Italian pediatric diabetologists about COVID-19 vaccination in children and adolescents with type 1 diabetes","volume":"59","author":"Scaramuzza","year":"2022","journal-title":"Acta Diabetol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/pedi.13326","article-title":"COVID-19 vaccination in adolescents and young adults with type 1 diabetes: Glycemic control and side effects","volume":"23","author":"Piccini","year":"2022","journal-title":"Pediatr Diabetes"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-022-01968-y","article-title":"The impact of COVID-19 vaccination on glycaemic control in children and adolescents with type 1 diabetes mellitus on continuous glucose monitoring","volume":"59","author":"Gouda","year":"2022","journal-title":"Acta Diabetol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41574-020-00435-4","article-title":"COVID-19 and diabetes mellitus: From pathophysiology to clinical management","volume":"17","author":"Lim","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.2337\/ds16-0068","article-title":"Acute hyperglycemia after influenza vaccination in a patient with type 2 diabetes","volume":"31","author":"Glaess","year":"2018","journal-title":"Diabetes Spectrum"},{"key":"B28","doi-asserted-by":"publisher","first-page":"109022","DOI":"10.1016\/j.diabres.2021.109022","article-title":"Short-term safety profile of sars-Cov2 vaccination on glucose control: Continuous glucose monitoring data in people with autoimmune diabetes","volume":"179","author":"D'Onofrio","year":"2021","journal-title":"Diabetes Res Clin Practice"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.33590\/emjdiabet\/21-00263","article-title":"Acute worsening of glycaemic control in a patient with latent autoimmune diabetes of adulthood after receiving the COVID-19 vaccine","author":"Altomare","year":"2022","journal-title":"EMJ Diabet"},{"key":"B30","doi-asserted-by":"publisher","first-page":"454","DOI":"10.3390\/vaccines10030454","article-title":"COVID-19 vaccines and hyperglycemia-is there a need for postvaccination surveillance","volume":"10","author":"Samuel","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-009-0109-4","article-title":"Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes","volume":"47","author":"Yang","year":"2010","journal-title":"Acta Diabetol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"677","DOI":"10.3390\/ph15060677","article-title":"European Safety analysis of mRNA and viral vector COVID-19 vaccines on glucose metabolism events","volume":"15","author":"di Mauro","year":"2022","journal-title":"Pharm (Basel Switzerland)"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.3390\/jcm11061564","article-title":"Effect of hyperglycemia on COVID-19 outcomes: Vaccination efficacy, disease severity, and molecular mechanisms","volume":"11","author":"Sardu","year":"2022","journal-title":"J Clin Med"},{"key":"B34","first-page":"291","article-title":"Impact of dose adjustment for normal eating (DAFNE) courses on glycemia, incidence of severe hypoglycemia, and episodes of diabetic ketoacidosis in people with type 1 diabetes","volume":"48","author":"Taghadom","year":"2022","journal-title":"Sci Diabetes Self Manag Care"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-0954","article-title":"Effects of COVID-19 lockdown on glucose control: Continuous glucose monitoring data from people with diabetes on intensive insulin therapy","volume":"43","author":"Maddaloni","year":"2020","journal-title":"Diabetes Care"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1120384\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T05:50:31Z","timestamp":1679291431000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1120384\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,20]]},"references-count":35,"alternative-id":["10.3389\/fendo.2023.1120384"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2023.1120384","relation":{},"ISSN":["1664-2392"],"issn-type":[{"type":"electronic","value":"1664-2392"}],"subject":[],"published":{"date-parts":[[2023,3,20]]},"article-number":"1120384"}}